Inhaltsverzeichnis
Auswahl der wissenschaftlichen Literatur zum Thema „Cancer immunity“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Cancer immunity" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Cancer immunity"
Michael, J. Dochniak. „Maladaptive Immunity and Metastasizing Cancer“. Cancer Medicine Journal 3, Nr. 1 (30.06.2020): 31–34. http://dx.doi.org/10.46619/cmj.2020.3-1017.
Der volle Inhalt der QuellePersing, David H., und Franklyn G. Prendergast. „Infection, Immunity, and Cancer“. Archives of Pathology & Laboratory Medicine 123, Nr. 11 (01.11.1999): 1015–22. http://dx.doi.org/10.5858/1999-123-1015-iiac.
Der volle Inhalt der QuelleKazbarienė, Birutė. „Tumor and immunity“. Medicina 45, Nr. 2 (10.02.2009): 162. http://dx.doi.org/10.3390/medicina45020021.
Der volle Inhalt der QuelleUrushizaki, Ichiro, und Yutaka Kohgo. „Cancer and immunity“. Japanese Journal of Clinical Immunology 8, Nr. 1 (1985): 1–14. http://dx.doi.org/10.2177/jsci.8.1.
Der volle Inhalt der QuelleSteinle, Alexander, und Adelheid Cerwenka. „MULT1plying cancer immunity“. Science 348, Nr. 6230 (02.04.2015): 45–46. http://dx.doi.org/10.1126/science.aaa9842.
Der volle Inhalt der QuelleBekeschus, Sander, Thomas von Woedtke, Klaus-Dieter Weltmann und Hans-Robert Metelmann. „Plasma, Cancer, Immunity“. Clinical Plasma Medicine 9 (Februar 2018): 13–14. http://dx.doi.org/10.1016/j.cpme.2017.12.021.
Der volle Inhalt der QuelleHeidari, Alireza, Katrina Schmitt, Maria Henderson und Elizabeth Besana. „Hereditary immunity in cancer“. International Journal of Advanced Chemistry 8, Nr. 1 (28.04.2020): 94. http://dx.doi.org/10.14419/ijac.v8i1.30607.
Der volle Inhalt der QuelleHiam-Galvez, Kamir J., Breanna M. Allen und Matthew H. Spitzer. „Systemic immunity in cancer“. Nature Reviews Cancer 21, Nr. 6 (09.04.2021): 345–59. http://dx.doi.org/10.1038/s41568-021-00347-z.
Der volle Inhalt der QuelleRathmell, Jeffrey C. „Obesity, Immunity, and Cancer“. New England Journal of Medicine 384, Nr. 12 (25.03.2021): 1160–62. http://dx.doi.org/10.1056/nejmcibr2035081.
Der volle Inhalt der QuelleOrzołek, Izabela, Jan Sobieraj und Joanna Domagała-Kulawik. „Estrogens, Cancer and Immunity“. Cancers 14, Nr. 9 (30.04.2022): 2265. http://dx.doi.org/10.3390/cancers14092265.
Der volle Inhalt der QuelleDissertationen zum Thema "Cancer immunity"
Zunino, Barbara. „Dialogue entre le métabolisme et l’immunité dans le traitement des cancers“. Thesis, Nice, 2014. http://www.theses.fr/2014NICE4113.
Der volle Inhalt der QuelleThe link between cell metabolism and cancer at the cellular level has long been known. Caloric restriction (CR) is known to prolong lifespan and to protect from cancer incidence. The molecular mechanisms involved in these benefic effects have been evaluated and may offer new opportunities for therapeutic intervention. Moreover, CR and CR-mimetics such as 2-deoxyglucose (2DG) has been shown to enhance chemotherapy efficiency and to induce an anti-cancer immune response. During the period of my PhD I demonstrated how the modulation of metabolism through caloric restriction or through its mimetics could significantly reduce the expression of the anti-apoptotic protein Mcl-1 and sensitize lymphoma-bearing mice to apoptosis induced by a Bcl-2/XL inhibitor, ABT-737. We have demonstrated that CR can control Mcl-1 translation and sensitize cells to ABT-737-induced death regardless of the presence or absence of p53 and/or of the main “BH3-only proteins”. Then, I focused on deciphering the molecular mechanisms allowing the Hyper-thermic Intra-Peritoneal Chemotherapy (HIPEC) to be beneficial to patients suffering from peritoneal carcinomatosis. Part of the protective effect was mediated through the induction of an efficient anti-cancer immune response. Next, I showed the involvement of heat shock proteins 90 (Hsp90) in the observed effect. Indeed, when Hsp90 was blocked we lost the protection induced by the HIPEC-treated cells, therefore underling the role of Hsp90 in this HIPEC-dependent induction of anti-cancer immune response
They, Laetitia. „Renforcement des effets immunomodulateurs d’un anticorps monoclonal anti-tumoral : étude des effets potentialisateurs de thérapies combinées et analyse des mécanismes impliqués“. Thesis, Montpellier, 2018. http://www.theses.fr/2018MONTT076/document.
Der volle Inhalt der QuelleMelanoma is the most aggressive form of skin cancer. Although early management is of good prognosis, the survival of patients decrease dramatically for metastatic stages. Despite the recent spectacular therapeutic advances, the major problem lies in resistance to treatment and relapse and the main challenge now is to develop an effective and sustainable control. Monoclonal antibodies (mAbs) have the ability to specifically target and eliminate tumor cells while recruiting cells from the immune system, to develop and / or enhance the immunity of the host with the development of a vaccinal immune response. In a solid tumor model of murine melanoma after subcutaneous transplantation of B16F10 cells, we investigated the immunomodulatory effect of TA99 mAb targeting a TYRP-1 surface antigen overexpressed in tumor melanocytes. Our results showed that about 30% of mice are protected in the long term and have an antitumoral humoral and cellular immune response. Moreover, the analysis of the immune infiltrate in mice that escape to the treatment with TA99 mAb and develop a tumor, shows an overexpression of PD-1 and Tim3 associated with a loss of effector cell functions within the tumor. This same phenotype has been observed in biopsies of patients with metastatic melanoma. Thus, blocking the PD-1 / PDL-1 axis by inoculation of an anti-PD1 mAb at the time of tumor escape potentiates the anti-tumor immune response and results in increased survival. However, the absence of complete regression suggests the establishment of other immunosuppressive pathways. Indeed we have observed an overexpression of CD39 and CD73 ectonucleotidases in the tumor microenvironment suggesting the involvement of adenosine in the resistance mechanisms observed and opening interesting perspectives for the concomitant blocking of this pathway and the PD1 / PDL-1 axis. Another strategy has been to improve the early immunomodulatory effects of TA99 mAb by combining it with oxaliplatin, a chemotherapy that promotes immunogenic death. Although the therapeutic combinations tested in this study showed encouraging in vivo effects with a significant delay in overall survival, no significant increase in the long-term anti-tumor response was observed, suggesting the establishment of other non-redundant immunosuppressive mechanisms or unsuitable combinations strategies. Both phenotypic and functional analysis of the different cellular actors of the tumor microenvironment will be a key step in the implementation of relevant combinations in association with the TA99 mAb. This work is highlighted by a phase I clinical trial (IMC-20D7S) using flanvotumab (human equivalent of mAb TA99) in 27 patients with metastatic melanoma that shows interesting clinical outcome without severe side effects, opening the way for the development of therapeutic combinations associated with this mAb
Zunino, Barbara. „Dialogue entre le métabolisme et l’immunité dans le traitement des cancers“. Electronic Thesis or Diss., Nice, 2014. http://www.theses.fr/2014NICE4113.
Der volle Inhalt der QuelleThe link between cell metabolism and cancer at the cellular level has long been known. Caloric restriction (CR) is known to prolong lifespan and to protect from cancer incidence. The molecular mechanisms involved in these benefic effects have been evaluated and may offer new opportunities for therapeutic intervention. Moreover, CR and CR-mimetics such as 2-deoxyglucose (2DG) has been shown to enhance chemotherapy efficiency and to induce an anti-cancer immune response. During the period of my PhD I demonstrated how the modulation of metabolism through caloric restriction or through its mimetics could significantly reduce the expression of the anti-apoptotic protein Mcl-1 and sensitize lymphoma-bearing mice to apoptosis induced by a Bcl-2/XL inhibitor, ABT-737. We have demonstrated that CR can control Mcl-1 translation and sensitize cells to ABT-737-induced death regardless of the presence or absence of p53 and/or of the main “BH3-only proteins”. Then, I focused on deciphering the molecular mechanisms allowing the Hyper-thermic Intra-Peritoneal Chemotherapy (HIPEC) to be beneficial to patients suffering from peritoneal carcinomatosis. Part of the protective effect was mediated through the induction of an efficient anti-cancer immune response. Next, I showed the involvement of heat shock proteins 90 (Hsp90) in the observed effect. Indeed, when Hsp90 was blocked we lost the protection induced by the HIPEC-treated cells, therefore underling the role of Hsp90 in this HIPEC-dependent induction of anti-cancer immune response
Decque, Adrien. „Etude de la SUMOylation dans l’immunité innée et l’oncogenèse“. Thesis, Paris 6, 2014. http://www.theses.fr/2014PA066312/document.
Der volle Inhalt der QuelleSUMOylation is a reversible post-translational modification modifying the functions of hundreds ofproteins. It is implicated in essential cellular and organismal processes, such as nuclear shuttling, DNArepair, mitosis, transcription. Using genetically modified models, deficient for the uniqueSUMOylation E2 enzyme UBC9, we characterized the consequences of a decrease in globalSUMOylation in two processes: innate immunity and oncogenesis.We reveal a major role for SUMOylation in the negative regulation of the gene coding for IFN-.Deregulation of this gene in the absence of Ubc9 has dramatic consequences on innate immunity, withincreased inflammatory transcriptional program expression, endotoxic shock hypersensitivity, andprotection against viral infection. Chromatin binding profile analysis of SUMO surrounding the Ifnb1gene revealed three new putative regulatory domains. Finally, SUMOylation regulates endogenousretroviruses expression, potential triggers for interferon response.Our second research axis allowed the characterization of the consequences of global SUMOylationdecrease on cellular transformation and colorectal oncogenesis. Our results show increased sensitivityof transformed cells to SUMOylation loss, when compared to primary cells. Furthermore, decreasingUBC9 levels by half causes a two-fold decrease in intestinal polyp numbers developing in the colon ofmice, in a chemically-induced model of colorectal oncogenesis.Altogether, these results helped increasing our knowledge of the role of SUMOylation in majorcellular processes implicated in oncogenesis and innate immunity
Meyer, Andrea Michael. „Ro52 in innate immunity, proliferation control and cancer /“. Zürich : ETH, 2009. http://e-collection.ethbib.ethz.ch/show?type=diss&nr=18198.
Der volle Inhalt der QuelleAl, Khathami Ali Gaithan. „Towards gastric cancer immunotherapy : assessment of cancer immunity and potential immune targets“. Thesis, University of Birmingham, 2018. http://etheses.bham.ac.uk//id/eprint/8855/.
Der volle Inhalt der QuelleTitu, Liviu. „Specific cytotoxic lymphocyte immunity against telomerase in colorectal cancer“. Thesis, University of Hull, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.273656.
Der volle Inhalt der QuelleGajurel, Damodar. „Boosting Anti-Cancer Immunity with a Novel Chimeric Molecule“. Thesis, Griffith University, 2017. http://hdl.handle.net/10072/370742.
Der volle Inhalt der QuelleThesis (Masters)
Master of Medical Research (MMedRes)
School of Medical Science
Griffith Health
Full Text
Lemay, Chantal. „Harnessing Oncolytic Virus-mediated Anti-tumour Immunity“. Thèse, Université d'Ottawa / University of Ottawa, 2012. http://hdl.handle.net/10393/23318.
Der volle Inhalt der QuelleAloulou, Nijez. „Rôle de la leptine dans le cancer colorectal humain“. Thesis, Paris Est, 2008. http://www.theses.fr/2008PEST0027.
Der volle Inhalt der QuelleCancer of the colon and rectum (CRC) is a real challenge in Western countries because of the prevalence, cost and bad prognosis. With they 37,000 new cases each year and 15% of mortality it is currently the 2nd cause of cancer death in France. Despite significant advances in diagnosis and treatment over the past decade, it remains with bad prognosis. Genetic and environmental factors were involved in the genesis of this cancer. Molecular characterization of CRC leaded to the identification of gene instability (MSI) in tumors with mismatch repair (MMR) abnormalities. This is found frequently (80%) the CRC hereditary no polyposis colon cancer family (HNPCC) and rarely (15%) in sporadic cancers. Those tumors with MSI phenotype are considered to be of good prognosis. The possible role of food and particulary energy balance on the occurrence of MMR abnormalities has been suggested. Several hormones including leptin have been reported to promote tumour growth. In addition, leptin may regulate immune response tin GIT. Its pro immunogenic effect results from cytokines production by gastrointestinal epithelial cells as well as its ability to control the proliferation of lymphocytes. We hypothesised that leptin might regulate anti tumour immune response. The analysis of prospective data from 171 patients with CRC showed that overexpression of leptin receptor in subset of tumours. Relationships between leptin recptor and tumour immune response have been studied in the tumour microenvironment in human tissues, and in culture cells in vitro as well as in animal models in vivo. Results showed intensity of immune response was depended on the level of leptin receptor expression and MSI in colon tumour cells. Thus leptin receptor expression may be considered as a prognostic marker in colon and rectal cancer in human
Bücher zum Thema "Cancer immunity"
E, Reif Arnold, Mitchell Malcolm S und Biological Response Modifier Program (U.S.), Hrsg. Immunity to cancer. Orlando: Academic Press, 1985.
Den vollen Inhalt der Quelle findenBo, Dupont, Hrsg. Immunity to cancer. Copenhagen: Munksgaard, 2002.
Den vollen Inhalt der Quelle findenE, Macher, und Sorg Clemens, Hrsg. Local immunity in cancer. Münster: Wissenschaftliche Verlagsgesellschaft Regensberg & Biermann, 1986.
Den vollen Inhalt der Quelle findenRaz, Yirmiya, und Taylor Anna N, Hrsg. Alcohol, immunity, and cancer. Boca Raton: CRC Press, 1993.
Den vollen Inhalt der Quelle findenOrentas, Rimas, James W. Hodge und Bryon D. Johnson, Hrsg. Cancer Vaccines and Tumor Immunity. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2007. http://dx.doi.org/10.1002/9780470170113.
Der volle Inhalt der QuelleSeya, Tsukasa, Misako Matsumoto, Keiko Udaka und Noriyuki Sato, Hrsg. Inflammation and Immunity in Cancer. Tokyo: Springer Japan, 2015. http://dx.doi.org/10.1007/978-4-431-55327-4.
Der volle Inhalt der QuelleOrentas, Rimas. Cancer vaccines and tumor immunity. Hoboken, N.J: Wiley-Interscience, 2008.
Den vollen Inhalt der Quelle findenRimas, Orentas, Hodge James W und Johnson Bryon D, Hrsg. Cancer vaccines and tumor immunity. Hoboken, N.J: John Wiley & Sons, 2008.
Den vollen Inhalt der Quelle findenRay, P. K., Hrsg. Advances in Immunity and Cancer Therapy. New York, NY: Springer New York, 1986. http://dx.doi.org/10.1007/978-1-4613-9558-4.
Der volle Inhalt der QuelleRay, P. K. Advances in Immunity and Cancer Therapy. New York, NY: Springer New York, 1985. http://dx.doi.org/10.1007/978-1-4612-5068-5.
Der volle Inhalt der QuelleBuchteile zum Thema "Cancer immunity"
Mora, Javier, Warner Alpízar-Alpízar und Andreas Weigert. „Cancer Immunity“. In Nijkamp and Parnham's Principles of Immunopharmacology, 191–208. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-10811-3_12.
Der volle Inhalt der QuelleTu, Shi-Ming. „Cancer Immunity“. In Cancer Treatment and Research, 147–59. Boston, MA: Springer US, 2010. http://dx.doi.org/10.1007/978-1-4419-5968-3_14.
Der volle Inhalt der QuelleCarlberg, Carsten, und Eunike Velleuer. „Cancer Immunity“. In Cancer Biology: How Science Works, 129–46. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-75699-4_10.
Der volle Inhalt der QuelleHuang, Gonghua. „Innate Immunity“. In Encyclopedia of Cancer, 1–5. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-27841-9_3064-6.
Der volle Inhalt der QuelleSchwab, Manfred. „Adaptive Immunity“. In Encyclopedia of Cancer, 1. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27841-9_74-2.
Der volle Inhalt der QuelleHuang, Gonghua. „Innate Immunity“. In Encyclopedia of Cancer, 2282–86. Berlin, Heidelberg: Springer Berlin Heidelberg, 2017. http://dx.doi.org/10.1007/978-3-662-46875-3_3064.
Der volle Inhalt der QuelleGratama, Jan W., Cor H. J. Lamers und Reno Debets. „A10 Cancer immunity“. In Principles of Immunopharmacology, 151–78. Basel: Birkhäuser Basel, 2011. http://dx.doi.org/10.1007/978-3-0346-0136-8_10.
Der volle Inhalt der QuelleSharifi, Laleh. „Nutrition and Cancer“. In Nutrition and Immunity, 283–300. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16073-9_13.
Der volle Inhalt der QuelleSilva, Lindsey M., und Jae U. Jung. „Autophagy and Immunity“. In Autophagy and Cancer, 145–65. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-6561-4_8.
Der volle Inhalt der QuelleAbolhassani, Hassan, Niyaz Mohammadzadeh Honarvar, Terezie T. Mosby und Maryam Mahmoudi. „Nutrition, Immunity, and Cancers“. In Cancer Immunology, 533–44. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-30845-2_24.
Der volle Inhalt der QuelleKonferenzberichte zum Thema "Cancer immunity"
Pittet, Mikael. „Abstract IA04: Cancer-promoting immunity“. In Abstracts: AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment; February 26 — March 1, 2014; San Diego, CA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.chtme14-ia04.
Der volle Inhalt der QuelleLeslie, Christina S. „Decoding Epigenomic Programs in Immunity and Cancer“. In BCB '19: 10th ACM International Conference on Bioinformatics, Computational Biology and Health Informatics. New York, NY, USA: ACM, 2019. http://dx.doi.org/10.1145/3307339.3342129.
Der volle Inhalt der QuelleZou, Weiping. „Abstract IA18: Metabolic impact on cancer immunity“. In Abstracts: AACR Special Conference on Advances in Ovarian Cancer Research; September 13-16, 2019; Atlanta, GA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1557-3265.ovca19-ia18.
Der volle Inhalt der QuelleIsaeva, O. G., und V. A. Osipov. „Photodynamic therapy influence on anti-cancer immunity“. In Saratov Fall Meeting 2009, herausgegeben von Valery V. Tuchin und Elina A. Genina. SPIE, 2009. http://dx.doi.org/10.1117/12.853588.
Der volle Inhalt der QuelleOuni, Rim, Ying Henderson, Yunyun Chen, Naimah Turner, William Padron, Ali Dadbin, Elena McBeath Fujiwara et al. „Characterization of Altered immunity in Anaplastic Thyroid Cancer“. In Leading Edge of Cancer Research Symposium. The University of Texas at MD Anderson Cancer Center, 2022. http://dx.doi.org/10.52519/00072.
Der volle Inhalt der QuelleMilani, Valeria, Veit Buecklein und Rolf Dieter Issels. „Abstract B11: Hyperthermia and antitumor immunity“. In Abstracts: AACR International Conference on Translational Cancer Medicine--; Mar 21–24, 2010; Amsterdam, The Netherlands. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1078-0432.tcme10-b11.
Der volle Inhalt der QuelleKudo-Saito, Chie, Masayoshi Toyoura, Yuji Shoya, Akiko Ishida und Ryoko Kon. „Abstract 3224: Blocking FSTL1 reprograms cancer-caused abnormal immunity“. In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-3224.
Der volle Inhalt der QuelleKhan, Mohammad W., Shingo Tsuji, MengXi Tian, Nairika Meshgin, Shea Grenier, Matthew J. Giacalone und Kathleen L. McGuire. „Abstract A05: Immunity, the colonic environment, and colon cancer“. In Abstracts: AACR Special Conference: The Function of Tumor Microenvironment in Cancer Progression; January 7-10, 2016; San Diego, CA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.tme16-a05.
Der volle Inhalt der QuelleStromnes, Ingunn M., Scott Brockenbrough, Thomas M. Schmitt, Jennifer D. Hotes, Markus A. Carlson, Carlos Cuevos, Philip D. Greenberg und Sunil R. Hingorani. „Abstract PR10: Re-engineering immunity to treat pancreas cancer“. In Abstracts: AACR Special Conference on Pancreatic Cancer: Innovations in Research and Treatment; May 18-21, 2014; New Orleans, LA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.panca2014-pr10.
Der volle Inhalt der QuelleMittendorf, Elizabeth A., Gheath Alatrash, Na Qiao, Haile Xiao, Pariya Sukhumalchandra, Kathryn Quintanilla, Karen Clise-Dwyer und Jeffrey Molldrem. „Abstract 801: Uptake of exogenous neutrophil elastase by breast cancer cells: A novel link between innate immunity, inflammation and breast cancer immunity“. In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-801.
Der volle Inhalt der QuelleBerichte der Organisationen zum Thema "Cancer immunity"
Andersen, Barbara L. Stress and Immunity Breast Cancer Project. Fort Belvoir, VA: Defense Technical Information Center, September 2001. http://dx.doi.org/10.21236/ada398948.
Der volle Inhalt der QuelleAndersen, Barbara L. Stress and Immunity Breast Cancer Project. Fort Belvoir, VA: Defense Technical Information Center, September 1997. http://dx.doi.org/10.21236/ada334925.
Der volle Inhalt der QuelleEck, Stephen, und Heike Boxhorn. Gene Therapy Mediated Breast Cancer Immunity. Fort Belvoir, VA: Defense Technical Information Center, September 1997. http://dx.doi.org/10.21236/ada335064.
Der volle Inhalt der QuelleNesbit, Heike K. Gene Therapy Mediated Breast Cancer Immunity. Fort Belvoir, VA: Defense Technical Information Center, September 1999. http://dx.doi.org/10.21236/ada382694.
Der volle Inhalt der QuelleWeinberg, Andrew D. Enhancing Anti-Prostate Cancer Immunity through OX40 Engagement. Fort Belvoir, VA: Defense Technical Information Center, Februar 2005. http://dx.doi.org/10.21236/ada437192.
Der volle Inhalt der QuelleVieweg, Johannes. Enhancement of Anti-Telomerase Immunity Against Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, November 2007. http://dx.doi.org/10.21236/ada485726.
Der volle Inhalt der QuelleVieweg, Johannes W. Enhancement of Anti-Telomerase Immunity Against Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, November 2005. http://dx.doi.org/10.21236/ada444923.
Der volle Inhalt der QuelleWeinberg, Andrew D. Enhancing Anti-Prostate Cancer Immunity Through OX40 Engagement. Fort Belvoir, VA: Defense Technical Information Center, Februar 2006. http://dx.doi.org/10.21236/ada455612.
Der volle Inhalt der QuelleIoannides, Constantin G. Epitope Specific T Cell Immunity to Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, Juni 2002. http://dx.doi.org/10.21236/ada414361.
Der volle Inhalt der QuelleWeinberg, Andrew D. Enhancing Anti-Prostate Cancer Immunity Through OX40 Engagement. Fort Belvoir, VA: Defense Technical Information Center, Februar 2004. http://dx.doi.org/10.21236/ada422213.
Der volle Inhalt der Quelle